Soft tissue sarcomas (STS) constitute an uncommon and heterogeneous group of tumours of mesenchymal cell origin. STS can arise anywhere in the body and at any age. Although STS comprise more than 50 different histopathological subtypes, they share several clinicopathological features and are usually considered as a group for diagnostic and therapeutic purposes.
STS require a multidisciplinary and complex therapeutic approach, involving pathologists, radiologists, surgeons, and radiation and medical oncologists, and should preferably be treated at specialist centres.
The challenges facing clinicians is that the symptoms of benign and malignant STS often overlap and despite there being key prevalent warning signs, diagnosis can often be delayed by several months. Early recognition and referral to a specialist centre that provides a multidisciplinary diagnosis and therapeutic approach are important factors for improving the outcomes of patients with STS.
Another challenge is deciding the optimal drug sequences and treatment formats to use, as some tumour types are especially sensitive to certain drugs, so clear guidance is needed to understand these sequences and also which new and emerging therapies are available for STS patients.
We're delighted to produce an article series on the challenges of Sarcoma in collaboration with the Clinical Sarcoma Research journal, comprising of review articles written by leading global experts in the field, which we encourage you to read below.